Free Trial

Ascendis Pharma A/S (ASND) Stock Price, News & Analysis

Ascendis Pharma A/S logo
$154.68 -3.26 (-2.06%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$154.59 -0.09 (-0.06%)
As of 03/28/2025 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ascendis Pharma A/S Stock (NASDAQ:ASND)

Key Stats

Today's Range
$154.00
$158.55
50-Day Range
$119.49
$168.84
52-Week Range
$111.09
$169.37
Volume
289,067 shs
Average Volume
465,825 shs
Market Capitalization
$9.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$204.64
Consensus Rating
Moderate Buy

Company Overview

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Remove Ads

Ascendis Pharma A/S Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

ASND MarketRank™: 

Ascendis Pharma A/S scored higher than 63% of companies evaluated by MarketBeat, and ranked 391st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ascendis Pharma A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Ascendis Pharma A/S has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Ascendis Pharma A/S's stock forecast and price target.
  • Earnings Growth

    Earnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.34) to $0.24 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ascendis Pharma A/S is -21.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ascendis Pharma A/S is -21.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Ascendis Pharma A/S's valuation and earnings.
  • Percentage of Shares Shorted

    12.03% of the float of Ascendis Pharma A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Ascendis Pharma A/S has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Ascendis Pharma A/S has recently increased by 10.05%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Ascendis Pharma A/S does not currently pay a dividend.

  • Dividend Growth

    Ascendis Pharma A/S does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.03% of the float of Ascendis Pharma A/S has been sold short.
  • Short Interest Ratio / Days to Cover

    Ascendis Pharma A/S has a short interest ratio ("days to cover") of 9.6.
  • Change versus previous month

    Short interest in Ascendis Pharma A/S has recently increased by 10.05%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Ascendis Pharma A/S has a news sentiment score of 1.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Ascendis Pharma A/S this week, compared to 6 articles on an average week.
  • Search Interest

    Only 5 people have searched for ASND on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Ascendis Pharma A/S's insider trading history.
Receive ASND Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter.

ASND Stock News Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Ascendis Pharma price target raised to $200 from $168 at JPMorgan
TD Cowen Sticks to Their Buy Rating for Ascendis Pharma (ASND)
TD Cowen Sticks to Its Buy Rating for Ascendis Pharma (ASND)
See More Headlines

ASND Stock Analysis - Frequently Asked Questions

Ascendis Pharma A/S's stock was trading at $137.67 at the beginning of 2025. Since then, ASND shares have increased by 12.4% and is now trading at $154.68.
View the best growth stocks for 2025 here
.

Ascendis Pharma A/S (NASDAQ:ASND) announced its quarterly earnings results on Wednesday, February, 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($1.32) by $0.64.

Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

Top institutional shareholders of Ascendis Pharma A/S include RA Capital Management L.P. (16.66%), Avoro Capital Advisors LLC (8.41%), FMR LLC (7.79%) and Artisan Partners Limited Partnership (7.33%).

Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
2/12/2025
Today
3/30/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ASND
Employees
1,017
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$204.64
High Stock Price Target
$289.00
Low Stock Price Target
$153.00
Potential Upside/Downside
+32.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-409,120,000.00
Net Margins
-104.54%
Pretax Margin
-102.64%

Debt

Sales & Book Value

Annual Sales
$363.64 million
Price / Cash Flow
N/A
Book Value
($1.88) per share
Price / Book
-82.28

Miscellaneous

Free Float
36,413,000
Market Cap
$9.39 billion
Optionable
Optionable
Beta
0.62

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:ASND) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners